Kamau Therapeutics presents follow-up data on nula-cel after side effects doomed Graphite Bio

SAN DIEGO — After Graphite Bio’s implosion, Matthew Porteus wants to do things differently.

The Stanford researcher’s stint at the biotech ended with Graphite selling itself in a reverse merger. The startup fell apart after the first patient in its lead program, a gene editing sickle cell…
Click here to view original post